Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children’s Hospital for Glioblastoma Multiforme

Shots:

• The exclusive WW collaboration agreement is to evaluate Mustang Bio’ s MB-101 (IL13Rα2-specific CAR) in combination with C134 for the treatment of glioblastoma multiforme
• The focus of the agreement is to assess the combination, inducing anti-tumor immune response when combined with CAR-T therapy targeting solid tumors 
• C134 is a herpes simplex virus type 1 (HSV-1) oncolytic virus, improving replication in tumors and is currently evaluated in P-I for patients with recurrent glioblastoma multiforme

Click here to read full press release/ article | Ref: Mustang Bio | Image: Ihsigns